Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, Whincup PH, Mukamal KJ, Gillum RF, Holme I, Njølstad I, Fletcher A, Nilsson P, Lewington S, Collins R, Gudnason V, Thompson SG, Sattar N, Selvin E, Hu FB, Danesh J, Emerging Risk Factors Collaboration. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med.2011; 364:829-41.
 Zhou M, Liu J, Hao Y, Liu J, Huo Y, Smith SC, Ge J, Ma C, Han Y, Fonarow GC, Taubert KA, Morgan L, Yang N, Xing Y, Zhao D, CCC-ACS Investigators. Prevalence and in-hospital outcomes of diabetes among patients with acute coronary syndrome in China: findings from the Improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome Project. Cardiovasc Diabetol. 2018; 17:147.
 Sethi SS, Akl EG, Farkouh ME. Diabetes mellitus and acute coronary syndrome: lessons from randomized clinical trials. Curr. Diab. Rep. 2012; 12:294-304.
 Hermans MP, Valensi P. Elevated triglycerides and low high-density lipoprotein cholesterol level as marker of very high risk in type 2 diabetes. Curr Opin Endocrinol Diabetes Obes. 2018; 25: 118-29.
 Dobiásová M. AIP--atherogenic index of plasma as a significant predictor of cardiovascular risk: from research to practice. Vnitr Lek. 2006; 52:64-71.
 Qin Z, Zhou K, Li YP, Cheng WJ, Wang ZJ, Wang JL, Gao F, Yang LX, Xu YK, Wu YF, He H and Zhou YJ. The atherogenic index of plasma plays an important role in predicting the prognosis of type 2 diabetic subjects undergoing percutaneous coronary intervention: results from an observational cohort study in China. Cardiovasc Diabetol. 2020; 19: 23.
 Yildiz G, Duman A, Aydin H, Yilmaz A, Hür E, Mağden K, Cetin G, Candan F. Evaluation of association between atherogenic index of plasma and intima-media thickness of the carotid artery for subclinic atherosclerosis in patients on maintenance hemodialysis. Hemodial Int.2013; 173:397-405.
 Icli A, Cure E, Uslu AU, Sakiz D, Cure MC, Ozucan M, Baykara RA, Karakoyun A, Balta S, Ozturk C, Arslan S, Kucuk A. The Relationship Between Atherogenic Index and Carotid Artery Atherosclerosis in Familial Mediterranean Fever. Angiology.2017;684:315-24.
 Fadaei R, Meshkani R, Poustchi H, Fallah S, Moradi N, Panahi G, Merat S, Golmohammadi T. Association of carotid intima media thickness with atherogenic index of plasma, apo B/apo A-I ratio and paraoxonase activity in patients with non-alcoholic fatty liver disease. Arch Physiol Biochem.2019;125: 19-24.
 Garg R, Knox N, Prasad S, Zinzuwadia S, Rech MA. The Atherogenic Index of Plasma is Independently Associated with Symptomatic Carotid Artery Stenosis. J Stroke Cerebrovasc Dis.2020;29: 105351.
 Choudhary MK, Eräranta A, Koskela J, Tikkakoski AJ, Nevalainen PI, Kähönen M, Mustonen J, Pörsti I. Atherogenic index of plasma is related to arterial stiffness but not to blood pressure in normotensive and never-treated hypertensive subjects. Blood Press.2019; 283:157-67.
 Nam JS, Kim MK, Nam JY, Park K, Kang S, Ahn CW, Park JS. Association between atherogenic index of plasma and coronary artery calcification progression in Korean adults. Lipids Health Dis.2020; 19:157.
 Cai G, Shi G, Xue S, Lu W. The atherogenic index of plasma is a strong and independent predictor for coronary artery disease in the Chinese Han population. Medicine. 2017;96:
 Wu TT, Gao Y, Zheng YY, Ma YT, Xie X. Atherogenic index of plasma (AIP): a novel predictive indicator for the coronary artery disease in postmenopausal women. Lipids Health Dis. 2018; 17:197.
 Guo Q, Zhou S, Feng X, Yang J, Qiao J, Zhao Y, Shi D, Zhou Y. The sensibility of the new blood lipid indicator--atherogenic index of plasma (AIP) in menopausal women with coronary artery disease. Lipids Health Dis. 2020; 19:27.
 Cai G, Liu W, Lv S, Wang X, Guo Y, Yan Z, Du Y, Zhou Y. Gender-specific associations between atherogenic index of plasma and the presence and severity of acute coronary syndrome in very young adults: a hospital-based observational study, Lipids Health Dis. 2019;18: 99.
 Wan K, Zhao J, Huang H, Zhang Q, Chen X, Zeng Z, Zhang L, Chen Y. The Association Between Triglyceride/High-Density Lipoprotein Cholesterol Ratio and All-Cause Mortality in Acute Coronary Syndrome After Coronary Revascularization. PLoS ONE. 2015; 10: e0123521.
 Zhu XW, Deng FY, Lei SF. Meta-analysis of atherogenic index of plasma and other lipid parameters in relation to risk of type 2 diabetes mellitus, Prim Care Diabetes.2015; 9:60-67.
 Li XL, Hong LF, Luo SH, Guo YL, Zhu CG, Sun J, Dong Q, Qing P, Xu RX, Liu J, Li S, Wu NQ, Liu G, Li JJ. Impact of admission triglyceride for early outcome in diabetic patients with stable coronary artery disease. Lipids Health Dis.2014; 13:73.
 Sharif S, van der Graaf Y, Nathoe HM, de Valk HW, Visseren FL, Westerink J, SMART Study Group. HDL Cholesterol as a Residual Risk Factor for Vascular Events and All-Cause Mortality in Patients with Type 2 Diabetes. Diabetes Care.2016;39:1424-30.
 Jin JL, Zhang HW, Cao YX, Liu HH, Hua Q, Li YF, Zhang Y, Wu NQ, Zhu CG, Xu RX, Gao Y, Li XL, Cui CJ, Liu G, Sun J, Dong Q, Guo YL, Li JJ. Association of small dense low-density lipoprotein with cardiovascular outcome in patients with coronary artery disease and diabetes: a prospective, observational cohort study. Cardiovasc Diabetol. 2020; 19:45.
 Salazar MR, Carbajal HA, Espeche WG, Aizpuru´ a M, Leiva Sisnieguez CE, March CE, Balbín E, Stavile RN, Reaven GM. Identifying cardiovascular disease risk and outcome: Use of the plasma triglyceride/high-density lipoprotein cholesterol concentration ratio versus metabolic syndrome criteria. J Intern Med. 2013; 273:595–601.
 Salazar MR, Carbajal HA, Espeche WG, Aizpuru´ a M, Leiva Sisnieguez CE, Leiva Sisnieguez BC, March CE, Stavile RN, Balbín E, Reaven GM. Use of the plasma triglyceride/high-density lipoprotein cholesterol ratio to identify cardiovascular diseasein hypertensive subjects. J Am Soc Hypertens. 2014;8: 724–31.
Edwards MK, Blaha MJ, Loprinzi PD. Atherogenic Index of Plasma and Triglyceride/High-Density Lipoprotein Cholesterol Ratio Predict Mortality Risk Better Than Individual Cholesterol Risk Factors, Among an Older Adult Population, Mayo Clin. Proc. 2017; 92:680-81.
Bendzala M, Sabaka P, Caprnda M, Komornikova A, Bisahova M, Baneszova R, Petrovic D. Atherogenic index of plasma is positively associated with the risk of all-cause death in elderly women: A 10-year follow-up.Wien. Klin. Wochenschr. 2017; 129: 793-98.
 Lee MJ, Park JT, Han SH, Kim YL, Kim YS, Yang CW, Kim NH, Kang SW, Kim HJ, Yoo TH. The atherogenic index of plasma and the risk of mortality in incident dialysis patients: Results from a nationwide perspective cohort in Korea. PLoS ONE.2017; 12: e0177499.
 Hartopo AB, Arso IA, Setianto BY. Low Plasma Atherogenic Index Associated with Poor Prognosis in Hospitalized Patients with Acute Myocardial Infarction.Acta Med Indones.2016;48:106-13.
 Laakso M. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes. 1999; 48:937-42.
 Zoppini G, Targher G, Negri C, Stoico V, Gemma ML, Bonora E, Usefulness of the triglyceride to high-density lipoprotein cholesterol ratio for predicting mortality risk in type 2 diabetes: Role of kidney dysfunction. Atherosclerosis. 2010; 212:287-91.
 Yang SH, Du Y, Li XL, Zhang Y, Li S, Xu RX, Zhu CG, Guo YL, Wu NQ, Qing P, Gao Y, Cui CJ, Dong Q, Sun J, Li JJ. Triglyceride to High-Density Lipoprotein Cholesterol Ratio and Cardiovascular Events in Diabetics with Coronary Artery Disease. Am J Med Sci. 2017; 354:117-24.
 Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC, Sperling L, Virani SS, Yeboah J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation.2019;139: e1082-143.
 Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund O, ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J.2020; 41:111-88.
 Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesäniemi YA, Sullivan D, Hunt D, Colman P, deaden M, Whiting M, Ehnholm C, Laakso M, FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial. Lancet. 2005; 366:1849-61.
 Scott R, O’Brien R, Fulcher G, Pardy C, D’Emden M, Tse D, Taskinen MR, Ehnholm C, Keech A, Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care. 2009; 32:493-98.
 Caminhotto Rde O, Fonseca FL, Castro NC, Arantes JP, Sertié RA. Atkins diet program rapidly decreases atherogenic index of plasma in trained adapted overweight men. Arch Endocrinol Metab.2015;59:568-71.
 Venojärvi M, Korkmaz A, Wasenius N, Manderoos S, Heinonen OJ, Lindholm H, Aunola S, Eriksson JG, Atalay M. 12 weeks' aerobic and resistance training without dietary intervention did not influence oxidative stress but aerobic training decreased atherogenic index in middle-aged men with impaired glucose regulation. Food Chem Toxicol.2013; 61:127-35.
 Golzari MH, Javanbakht MH, Ghaedi E, Mohammadi H, Djalali M. Effect of Eicosapentaenoic acid (EPA) supplementation on cardiovascular markers in patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled trial. Diabetes Metab Syndr .2018; 12:411-415.
 Jin JL, Zhang HW, Cao YX, Liu HH, Hua Q, Li YF, Zhang Y, Wu NQ, Zhu CG, Xu RX, Gao Y, Li XL, Cui CJ, Liu G, Sun J, Dong Q, Guo YL, Li JJ. Association of small dense low-density lipoprotein with cardiovascular outcome in patients with coronary artery disease and diabetes: a prospective, observational cohort study. Cardiovasc Diabetol.2020;19:45.
 Tan MH, Johns D, Glazer NB. Pioglitazone reduces atherogenic index of plasma in patients with type 2 diabetes. Clin Chem.2014;50: 1184-8.
 Onat A, Can G, Kaya H, Hergenç G. "Atherogenic index of plasma" (log10 triglyceride/high-density lipoprotein-cholesterol) predicts high blood pressure, diabetes, and vascular events. J Clin Lipidol. 2010; 4:89-98.
 Zhu X, Yu L, Zhou H, Ma Q, Zhou X, Lei T, Hu J, Xu W, Yi N, Lei S. Atherogenic index of plasma is a novel and better biomarker associated with obesity: a population-based cross-sectional study in China. Lipids Health Dis .2018;17: 37.
 Wang Q, Zheng D, Liu J, Fang L, Li Q. Atherogenic index of plasma is a novel predictor of non-alcoholic fatty liver disease in obese participants: a cross-sectional study. Lipids Health Dis .2018;17:284.